Aliases:This biomarker is also known as:
- matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase),
- neutrophil gelatinase,
- 72 kDa type IV collagenase,
- EC 22.214.171.124,
- Matrix metalloproteinase-2,
- matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase),
- 72 kDa gelatinase,
- collagenase type IV-A,
- Gelatinase A,
- matrix metalloproteinase-II,
MMP2 is a member of the matrix metalloproteinase (MMP) family and is involved in many functions, such as remodeling of the vasculature, angiogenesis, tissue repair and remodeling, tumor invasion, inflammation, atherosclerotic plaque rupture, reproduction and embryonic development, as well as in disease processes such as arthritis and metastasis. In addition to degrading extracellular matrix proteins, MMP2 can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction and appears to have a role in myocardial cell death pathways. MMPs are generally secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The MMP2 protein degrades gelatin type I and collagen types IV, V, VII, and X. MMP2 gene mutations have been associated with Winchester syndrome and Nodulosis-Arthropathy-Osteolysis (NAO) syndrome. There are two known isoforms of this gene, encoded by two transcript variants.
There are no datasets associated with this biomarker.